scholarly journals Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework

BMJ Open ◽  
2012 ◽  
Vol 2 (4) ◽  
pp. e000622 ◽  
Author(s):  
Ben Carter ◽  
Zbys Fedorowicz
Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3436-3436 ◽  
Author(s):  
Stuart Mealing ◽  
Leticia Barcena ◽  
Neil Hawkins ◽  
James Clark ◽  
Catherine Davis

Abstract Abstract 3436 Introduction: Historically, interferon-alpha, hydroxyurea or chemotherapy were used as first line therapy for individuals newly diagnosed with CML. Current practice, however, recommends that tyrosine-kinase inhibitors (TKIs) be used in this patient group, with imatinib (1st generation TKI) being the current standard of care. Recent publications provide data from randomized clinical trials on 2nd generation TKIs (dasatinib and nilotinib) in the first-line setting. In the absence of randomized head to head evidence for all three TKI's, a Bayesian mixed treatment comparison meta-analysis provides a means of indirectly estimating the treatment effect of one intervention relative to another. Methods: A systematic review identified RCTs that reported or summarized efficacy data for any of the treatments of interest in treatment-naive CML patients. In order to maximise the evidence network, RCT's of non-TKI's were also included in the review. Where reported, data was extracted for molecular, hematological and cytogenic response at three montly intervals. In addition, safety and progression free and overall survival data was extracted for all reported timepoints. Extracted data was analyzed in a Bayesian mixed treatment comparison using a fixed-effects model. The outputs from all analyses were expressed as odds ratios with Imatinib 400mg SID used as the baseline intervention in all analyses. Results: Overall, 44 articles arising from 19 distinct clinical trials were included in the review. The results for complete cytogenetic response (CCyR) at twelve months (expressed as both response probabilities and odds ratios) are presented in table 1. High dose imatinib performed no better than standard dose imatinib. However, response with both 2nd generation TKIs was significantly better than with standard dose imatinib with the effect size being doubled on all endpoints. Head to head results for nilotinib and dasatinib showed no statistically significant differences (p=0.05) between the two products on all endpoints (see table 2). Conclusions: Compared to Imatinib, the use of 2nd generation TKI's for the treatment of newly diagnosed CML results in a significant improvement in complete cytogenic response. However, the current evidence base is not rich enough to distinguish between the two 2nd generation TKIs either in terms of response or progression free survival. The analyses presented will be strengthened by the inclusion of additional RCT data that may become available in the future. Disclosures: Mealing: Oxford Outcomes: Employment. Barcena:Oxford Outcomes: Employment. Hawkins:Oxford Outcomes: Employment. Clark:Oxford Outcomes: Employment. Davis:Bristol Myers-Squibb: Employment.


2016 ◽  
Vol 4 (13) ◽  
pp. 1-304 ◽  
Author(s):  
Nicky Cullum ◽  
Hannah Buckley ◽  
Jo Dumville ◽  
Jill Hall ◽  
Karen Lamb ◽  
...  

BackgroundComplex wounds are those that heal by secondary intention and include lower-limb ulcers, pressure ulcers and some surgical wounds. The care of people with complex wounds is costly, with care mainly being delivered by community nurses. There is a lack of current, high-quality data regarding the numbers and types of people affected, care received and outcomes achieved.ObjectivesTo (1) assess how high-quality data about complex wounds can be captured effectively for use in both service planning and research while ensuring integration with current clinical data collection systems and minimal impact on staff time; (2) investigate whether or not a clinical register of people with complex wounds could give valid estimates of treatment effects, thus reducing dependence on large-scale randomised controlled trials (RCTs); (3) identify the most important research questions and outcomes for people with complex wounds from the perspectives of patients, carers and health-care professionals; (4) evaluate the potential contributions to decision-making of individual patient data meta-analysis and mixed treatment comparison meta-analysis; and (5) complete and update systematic reviews in topic areas of high priority.MethodsTo meet objectives 1 and 2 we conducted a prevalence survey and developed and piloted a longitudinal disease register. A consultative, deliberative method and in-depth interviews were undertaken to address objective 3. To address objectives 4 and 5 we conducted systematic reviews including mixed treatment comparison meta-analysis.ResultsFrom the prevalence survey we estimated the point prevalence of all complex wounds to be 1.47 per 1000 people (95% confidence interval 1.38 to 1.56 per 1000 people). Pressure ulcers and venous leg ulcers were the most common type of complex wound. A total of 195 people with a complex wound were recruited to a complex wounds register pilot. We established the feasibility of correctly identifying, extracting and transferring routine NHS data into the register; however, participant recruitment, data collection and tracking individual wounds in people with multiple wounds were challenging. Most patients and health professionals regarded healing of the wound as the primary treatment goal. Patients were greatly troubled by the social consequences of having a complex wound. Complex wounds are frequently a consequence of, and are themselves, a long-term condition but treatment is usually focused on healing the wound. Consultative, deliberative research agenda setting on pressure ulcer prevention and treatment with patients, carers and clinicians yielded 960 treatment uncertainties and a top 12 list of research priorities. Of 167 RCTs of complex wound treatments in a systematic review of study quality, 41% did not specify a primary outcome and the overall quality of the conduct and reporting of the research was poor. Mixed-treatment comparison meta-analysis in areas of high priority identified that matrix hydrocolloid dressings had the highest probability (70%) of being the most effective dressing for diabetic foot ulcers, whereas a hyaluronan fleece dressing had the highest probability (35%) of being the most effective dressing for venous ulcers; however, the quality of this evidence was low and uncertainty is high.ConclusionsComplex wounds are common and costly with a poor evidence base for many frequent clinical decisions. There is little routine clinical data collection in community nursing. A prospective complex wounds register has the potential to both assist clinical decision-making and provide important research evidence but would be challenging to implement without investment in information technology in NHS community services. Future work should focus on developing insights into typical wound healing trajectories, identifying factors that are prognostic for healing and assessing the cost-effectiveness of selected wound treatments.FundingThe National Institute for Health Research Programme Grants for Applied Research programme.


Sign in / Sign up

Export Citation Format

Share Document